I F Khouri, J Romaguera, H Kantarjian, J L Palmer, W C Pugh, M Korbling, F Hagemeister, B Samuels, A Rodriguez, S Giralt, A Younes, D Przepiorka, D Claxton, F Cabanillas, R Champlin
PURPOSE: Diffuse and nodular forms of mantle-cell lymphoma (MCL) are consistently associated with poor prognosis. In an effort to improve the outcome, we adopted a treatment plan that consisted of four courses of fractionated cyclophosphamide (CY) 1,800 mg/m2 administered with doxorubicin (DOX), vincristine (VCR), and dexamethasone (Hyper-CVAD) that alternated with high-dose methotrexate (MTX) and cytarabine (Ara-C). After four courses, patients were consolidated with high-dose CY, total-body irradiation, and autologous or allogeneic blood or marrow stem-cell transplantation...
December 1998: Journal of Clinical Oncology